Qiagen (QGEN) said the US Food and Drug Administration approved QIAstat-Dx Gastrointestinal Panel tests for clinical use.
The clearance covers QIAstat-Dx Gastrointestinal Panel 2 Mini bacterial and viral to identify five causes of gastrointestinal disease, the company said Thursday in a statement.
The company expects to file a second version of the panel covering common bacterial pathogens that cause gastrointestinal infections with the FDA for approval in the coming weeks.
Qiagen intends to submit an application for FDA clearance for a higher-capacity diagnostic instrument, QIAstat-Dx Rise, in early 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.